BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16822719)

  • 1. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
    Jiang H; Pierce GF; Ozelo MC; de Paula EV; Vargas JA; Smith P; Sommer J; Luk A; Manno CS; High KA; Arruda VR
    Mol Ther; 2006 Sep; 14(3):452-5. PubMed ID: 16822719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
    Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
    Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
    Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
    Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
    Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
    Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV-mediated gene transfer for hemophilia.
    High KA
    Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.
    Hauck B; Xu RR; Xie J; Wu W; Ding Q; Sipler M; Wang H; Chen L; Wright JF; Xiao W
    Hum Gene Ther; 2006 Jan; 17(1):46-54. PubMed ID: 16409124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and improved AAVenues: current status of hemophilia B gene therapy.
    Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
    Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.